As the organoid market is projected to boom to $15.01 billion by 2031, imaging, sequencing and analysis technologies to validate complex in vitro models advance, and the notoriously high failure rates of animal models in the clinic persists, it has never been a more critical time for pharma and biotech to leverage more physiologically relevant and predictive complex in vitro models to supercharge drug discovery and development.

Building on this need, the 10th Annual 3D Tissue Models Summit returns to Boston in May 2025 to provide an update on complex in vitro model advancements and uncover strategies to optimize validation, safeguard reproducibility and secure regulatory support.

With brand new content spanning early disease research through to toxicology, here’s what’s exciting this year:

• Probe the latest advancements in disease modelling: Delve into best practice to accurately recapitulate disease and ensure reproducibility across diverse complex in vitro models and supercharge oncology, immunology, neurology, respiratory, and metabolic research
• Bullet-proofing model validation workshop day: Deep dive into optimized tips and tricks to tackle cell sourcing and tissue accessibility, and assess the types of data needed from different assays to build a more standardized protocol and ensure better model validation
• Knowledge-transfer with your peers: You will have the unique opportunity to exchange challenges, inspire solutions with leading industry experts across dedicated speed-networking, speed learning and roundtable sessions as well as assess the latest technologies over the last 12 months
• Foster High-Impact Collaborations: Meet and network with carefully selected complex in vitro modelling providers, 3D bioprinters, imaging platform providers and researchers to advance your workflows